Business Context and Reporting Period
This Form 8-K is a current report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on December 16, 2021. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ALVR. The report discloses a material event regarding executive leadership changes.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure regarding personnel and does not contain financial statements or performance metrics.
Material Changes
- Executive Departure: The Company announced the departure of its Chief Medical Officer, Agustin Melian, MD, effective at the end of 2021.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlooks, or specific risk factors beyond the immediate impact of the executive departure. The press release detailing the departure is attached as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the exact effective date of Agustin Melian, MD's departure (stated as end of 2021).
- Review the attached press release (Exhibit 99.1) for details on the transition plan or interim leadership.
- Confirm the company name is AlloVir, Inc. (ALVR), as the input metadata incorrectly referenced Kalaris Therapeutics, Inc.